HC Wainwright upgraded Kyverna Therapeutics Inc. KYTX, citing three upcoming data sets through mid-2025. In its first quarter 2025 earnings released, the company highlighted: Enrollment is complete in the registrational Phase 2 KYV-101 trial for stiff person syndrome (SPS). The trial is on track for topline data and a biologics license application (BLA) filing is
Oklo Inc OKLO reported financial results for the first quarter after the market close on Tuesday. Here’s a rundown of the nuclear company’s report. Q1 Earnings: Nuclear startup Oklo reported a first-quarter loss of seven cents per share, improved from a loss of 34 cents per share in the prior year’s quarter, according to Benzinga
The U.S. Food and Drug Administration (FDA) on Thursday issued a Complete Response Letter for Aldeyra Therapeutics, Inc.’s ALDX resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for dry eye disease. The FDA stated that the NDA “failed to demonstrate efficacy in adequate and well-controlled studies in treating ocular symptoms associated
Analog Devices, Inc. ADI stock traded higher Wednesday after the company reported fiscal third-quarter results. The company’s revenue declined 25% year-on-year to $2.31 billion, beating the analyst consensus estimate of $2.27 billion. Adjusted EPS of $1.58 beat the analyst consensus estimate of $1.50. Analog Devices’ Industrial revenue declined by 37% year-on-year to $1.06 billion. Automotive revenue decreased 8% Y/year-on-year to $670.3 million. Communications revenue declined
BioRestorative Therapies, Inc. BRTX shares are trading higher Monday after the company announced it has received notice from the Nasdaq Stock Market that it has regained compliance with listing requirements. The Details: BioRestorative Therapies reported a net loss for the first quarter of $2.2 million, or 33 cents per share, compared to a net loss
Symbotic Inc SYM shares are tumbling in Monday’s after-hours session on the heels of the company’s third-quarter financial results. Q3 Earnings: Symbotic reported fiscal third-quarter revenue of $491.862 million, beating analyst estimates of $464.55 million, according to Benzinga Pro. The company reported an earnings loss of 2 cents per share, missing estimates for positive earnings